Neurodegenerative Diseases

Therapeutic targeting of toxic aggregates, detecting a-Syn, role liposome fusion, PD biomarker discovery in CSF and blood, non-coding RNA in PD. Techniques: Aptamer selection, , super resolution microscopy, lipid vesicle fusion, RNA biomarkers and sp

Synaptic protein networks and their vulnerabilities in brain diseases using in situ quantitative single-molecule visualization

Imaging biomarkers of neurodegenerative diseases for quantification of disease processes and prediction of disease progression. We work with MRI and PET and apply image processing and machine learning methods for modelling and prediction.

My main focus is the investigation of the prion-like spreading of alpha-synuclein along the gut-brain axis in wild-type and transgenic animal models of Parkinson’s disease, and the influence of different risk-factors on disease progression.

0

Novel and conventional neurophysiological methods for the assessment of CNS and PNS, such as NCS, EMG, single fiber EMG, TMS, MUNE, nerve excitability testing with threshold tracking and muscle excitability testing.

The systems-level molecular mechanisms of selective retention of trivial everday memory through neuromodulation and the assimilation of this retained memory into the relevant knowledge structure called ”schema”.

Revealing epigenetic and transcriptional basis of neuroplasticity in memory engram cell formation by applying state of the art genomics technologies.

We investigate sortilin and APP regulation with particular focus on proteolytic processing and modulation by protein interaction partners. In addition, we are interested in molecular mechanisms facilitating rapid antidepressant actions.

We are studying trafficking of proteins and lipids in neurodegenerative diseases. Main techniques used in the lab are quantitative live-cell fluorescence imaging, super-resolution and correlative microscopy combined with image analysis and AI.

Large animal models of neurodegenerative diseases

PET imaging in vivo molecular changes in rodent and minipig models of Parkinson’s disease and depression. Molecular mechanisms related to neuroinflammation, synaptic density and epigenetics, and examination of the efficacy of putative therapies.

Deep brain stimulation and perception for movement disorders

Structure-function of neuronal membrane proteins

We investigate  a-synuclein induced neurodegeneration and immune associated response in Parkinson’s disease and evaluate therapeutic strategies. In our studies we use animal models and patients’ samples. Anatomy, FCAS, histology, behavior, scRNA

Prodromal Parkinsonism with focus on small- and large fiber neuropathy and autonomic dysfunction using quantitative sudomotor axon reflex test, tilt table testing, Valsalva maneuver, deep respiration, 24-h BP, pupillometry, MIBG, and skin biopsies

My group is focusing on (1) better understanding the pathogenesis of neurodegenerative diseases by single cell and spatial multi-transcriptomics and (2) development of CRISPR-based gene therapy.

The role of the protein -synucleins aggregation in neurodegenerative diseases using molecular, cellular, brain slice and mouse models and disease modifying strategies. Techniques: protein chem., aggregation & immuno assays, quantitative microscopy.

Wearable devices for long-term monitoring of neural activity (EEG and EMG) and other physiological measures (including respiratory, cardiovascular, and vocal tract activity). Machine learning algorithms.  Long-term EEG and polysomnography monitoring.

Parkinson’s disease (PD) research. Multi-modal imaging with PET, SPECT, and MR. Defining PD subtypes in longitudinal cohort studies using imaging. Characterizing non-motor symptoms. Animal models of PD, and neuropathology. Gut-brain interaction in PD

We study autobiographical memory (i.e., memory for the personal past) in healthy and disordered populations, including dementia, using a variety of methodologies, such as diary studies, survey studies, experiments, and neuropsychological assessments

Molecular basis of α-synucleinopathies (particularly Parkinson’s) and therapeutic approaches against them using biophysical approaches. Mechanisms of α-syn aggregation and their inhibition by small molecules, peptides, nano- and antibodies.

Structural biology of menbeane transporters and receptors in brain related to ion homeostasis/gradients (Na, K, Ca, Cl, pH), amino acids/neurotransmitters (dopamine, metabolism, insulin) and polarity/plasticity (BDNF, FRMD7)

Developing and applying methods for imaging brain microstructure with MRI

Focus on clinical neuropsychiatry. CNSR hosts the CINS database containing a broad range of data (including psychopathology, cognition, EEG, neuroimaging and genetics) primarily on never-medication patients with psychosis and schizophrenia.

Use of PET imaging for clinical diagnosis and disease progression in PD and MSA, and linking in-vivo functional measures to structure.

Mouse models of Amyotrophic lateral sclerosis-Frontotemporal dementia, Behavioral assessment, Gene therapy, Multiplexing techniques: HiplexUP, RNAscope (ACD-Bio); Xenium (10X-Genomics), Spatial Transcriptomics: Nanostring GeoMX spatial profiling, Com

The focus of the Skotte Group is to explore protein alterations in Huntington’s disease to discover new biomarkers using human biofluids and to define novel drug targets using human induced pluripotent stem cells and murine single cell populations

We aim to reveal the molecular details of glycine and glutamine transport using a multidisciplinary approach including structural studies by Cryo-EM and/or X-ray crystallography, and a range of biophysical and biochemical methods.

Investigation of neuronal circuit function in rodents by use of viral tools (chemogenetic platforms). Viral platforms in combination with lesion models and neuroimaging to capture network/neurotransmitter changes in the cortico-basal ganglia circuit.

Our highly international group is interested in the function, structure and pharmacology of ion channels, which regulate neuronal excitability by controlling the flux of ions across cell membranes. Their dysfunction is associated with numerous diseases, resulting in an ever-increasing demand for new drugs targeting these proteins.

Linking clinical phenotypes in patients with motor neuron disease and atypical parkinsonism with clinical, biochemical, genetic, and neurophysiological biomarkers. Improvement of diagnosis, monitoring, and treatment.

Our research focuses on the understanding and treatment of neuromuscular diseases. We primarily use human tissue with techniques ranging from single molecule biophysics to muscle physiology and from advanced imaging to single cell proteomics.

Cognitive dysfunction in dementia using neuropsychological testing

We investigate how disruptions in lipid metabolism may lead to Parkinson’s Disease (PD) using biochemical, biophysical and omics methods to identify changes in lipid levels associated with PD and alpha-synuclein pathology in neurons and brain samples

Improve symptomatic treatment of Parkinson’s disease, incl. advanced treatment and Deep Brain Stimulation. Cognitive changes and rehabilitation. Treatment effects and imaging. Linking clinical phenotypes with biochemical and neuroimaging biomarkers

Systems cognitive neuroscience and its applications to dementia and parkinsonism. Multimodal integration and computational models of brain function. MEG, PET, MRI, neuropathology and drug trials.

Clinical PET and MRI on patients with neurodegenerative disorders, brain tumours, epilepsi and cerebrovascular disease. We have a subgroup using AI to process data. Our focus is on clinical implementation and diagnostic accuracy

My group studies neural plasticity and improved brain function after interventions such as cognitive or physical training, by using multimodal brain imaging techniques including structural and functional MRI and PET and behavioral testing

Structural biology on soluble and membrane proteins using crystallography and cryo-EM, with focus on ionotropic glutamate receptors and G protein-coupled receptors. Studies of protein-ligand interactions as basis for structure-based design.

Epidemiology of Alzheimer’s disease and other dementia disorders, risk factors, early symptoms and prognostic factors

Research Interests Mitochondrial dysfunction and immunological mechanisms in PD and dementia 1. Role of immune gene defects in neuronal homeostasis 2. How immune genes control the function of mitochondria to prevent neuroinflammation & PDDpropagation

Inherited neurodegenerative disorders (e.g. Huntington’s disease, Spinocerebellar ataxia type 2, CHMP2B-frontotemporal dementia); genotype/phenotype correlations; patient-derived iPSC neuronal models

Systems biology and health data integration in the brain disorder domain

Clinical research in diagnostic and prognostic biomarkers of neurodegenerative disorders, including biofluid and neuroimaging markers

Development and evaluation of community-based rehabilitation and palliative care interventions. Needs and experiences of people living with PD and/or Dementia in relation to public health services. Qualitative and survey methods, PPI-methods

Human Brain Mapping

Parkinsons’ disease pathogenesis (molecular and cellular mechanisms); identification of disease-modifying targets; role of neuron-glia interaction (stem cells; various biochemical, molecular and functional assays; bioimaging techniques).

User involvement and user perspectives, healthcare organization, communication, interprofessional collaboration, Patient Reported Outcomes (PRO) and Evidence Based Research